Papilloguard® 4 四价 HPV 疫苗与 Gardasil® 在 15–25 岁健康人群中的免疫原性与安全性 III 期试验
这项 III 期随机双盲非劣效试验纳入 670 名 15–25 岁健康受试者,比较 Papilloguard® 4(含 AS04 佐剂的四价 HPV 疫苗)与 Gardasil® 在第 0、2、6 月接种后的免疫原性与安全性。第 210 天 Papilloguard® 对四种 HPV 型别均显示非劣效免疫原性,各型抗体几何平均浓度持续高于 Gardasil®,但优效性分析未预设。多数不良事件为 1–2 级,局部反应性增加但总体安全性可接受。
要点
- Papilloguard® 4 对 HPV 6/11/16/18 型第 210 天免疫原性非劣于 Gardasil®。
- Papilloguard® 各型抗体几何平均浓度持续高于 Gardasil®,但优效性未预设。
- 局部反应性增加但总体安全性可接受,多数不良事件为 1–2 级。
核心结论
- Papilloguard® 4 对 HPV 6、11、16、18 型的免疫原性非劣于 Gardasil®。
- Papilloguard® 局部反应性较高但总体安全性可接受。
研究设计与样本
- III 期随机双盲非劣效试验,纳入 670 名 15–25 岁健康受试者。
- 疫苗于第 0、2、6 月接种,第 60、180、210 天评估 HPV 特异性抗体几何平均浓度。
主要发现
- 第 210 天 Papilloguard® 对四种 HPV 型别均显示非劣效免疫原性。
- Papilloguard® 各型抗体几何平均浓度持续高于 Gardasil®。
- 第 210 天 Papilloguard® 组 HPV 6、11、18 型血清阳转率更高,但优效性分析未预设。
- 两组各报告 2 例严重不良事件,均判定与疫苗无关。
关键数值与推荐
- 接种程序为第 0、2、6 月,共 3 剂。
- 免疫原性主要评估时间为第 60、180、210 天。
- 多数不良事件为 1 级或 2 级。
- 接种部位疼痛为两组最常见局部征集性不良事件。
- 头痛和乏力为最常见全身征集性不良事件。
临床怎么用
- Papilloguard® 4 可作为 15–25 岁人群 HPV 疫苗接种的候选选择。
- 接种时应告知局部反应性可能增加但总体安全性可接受。
局限性
- 优效性分析未预设,抗体浓度高于 Gardasil® 的发现需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Papilloguard® is developed by Nivad Pharmed Salamat as a quadrivalent human papillomavirus (HPV) vaccine, uniquely combined with the adjuvant system 04 (AS04). The objective of this study was to evaluate the immunogenicity and safety of the quadrivalent Papilloguard® in comparison with Gardasil® (Merck). METHODS: This study enrolled 670 healthy participants aged 15-25 years. Vaccines were administered at Months 0, 2, and 6. Immunogenicity was assessed by geometric mean concentrations of HPV-specific antibodies at days 60, 180, and 210. Safety data were collected through direct monitoring, phone follow-ups, and diary cards. RESULTS: Papilloguard® demonstrated non-inferior immunogenicity compared to Gardasil® across all four HPV types at day 210. Moreover, Papilloguard® demonstrated consistently higher geometric mean antibody concentrations across all four HPV types compared with Gardasil®. Seroconversion rates were also higher for HPV types 6, 11, and 18 at day 210 in the Papilloguard® group. However, superiority analyses were not prespecified and these findings should be interpreted cautiously. This enhanced immunogenicity may be associated with the AS04 in the quadrivalent formulation. Most reported adverse events were grade 1 or 2. Vaccination site pain was observed in both groups as the most commonly reported local solicited adverse event. Headache and fatigue were the most frequently reported systemic solicited adverse events. Two serious adverse events were reported in each group, none of which were considered related to the vaccines. While associated with increased local reactogenicity, the overall safety profile of Papilloguard® was acceptable and comparable to other HPV vaccines. CONCLUSION: Papilloguard®, the first quadrivalent HPV vaccine combined with AS04, demonstrated non-inferior immunogenicity compared to Gardasil® for HPV types 6, 11, 16, and 18. Despite a higher incidence of local reactogenicity, likely associated with AS04, Papilloguard® showed enhanced immunogenicity while maintaining an acceptable overall safety profile, positioning it as a promising HPV vaccine.
引用
- Mardani M, Darazam IA, Moini A, et al. Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. Vaccine. 2026. PMID: 42424856. doi:10.1016/j.vaccine.2026.128886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。